q********g
发帖数: 10694 | 1 http://finviz.com/quote.ashx?t=ATRC,BONE,CDXS,MRIC.OB,SRPT&ty=c
the link: http://seekingalpha.com/article/885411-5-healthcare-companies-with-insider-buying-during-september-2012?source=yahoo
5 Healthcare Companies With Insider Buying During September 2012
September 24, 2012 | 3 comments | includes: ATRC, BONE, CDXS, MRIC.OB,
SRPT
Disclosure: I am long BONE. (More...)
The Healthcare sector has been the top performing group during the last 6
months with a 11.4% gain during that period.
(click to enlarge)
Based on this observation I screened for companies in the healthcare sector
where at least one insider made a buy transaction during the September month
. Here is a look at five stocks that I found.
1. Bacterin International Holdings (BONE) develops, manufactures and markets
biologics products to domestic and international markets. Bacterin's
proprietary methods optimize the growth factors in human allografts to
create the ideal stem cell scaffold to promote bone, subchondral repair and
dermal growth. These products are used in a variety of applications
including enhancing fusion in spine surgery, relief of back pain, promotion
of bone growth in foot and ankle surgery, promotion of cranial healing
following neurosurgery and subchondral repair in knee and other joint
surgeries. Bacterin's Medical Device division develops, employs and licenses
bioactive coatings for various medical device applications. Bacterin's
strategic coating initiatives include antimicrobial coatings designed to
inhibit biofilm formation and microbial contamination.
(click to enlarge)
Insider buys
Guy Cook purchased 5,000 shares on September 11 and 95,451 shares during
May 9 - June 8 period. Guy Cook owns 25.2% of the company. Guy Cook serves
as a Chairman of the board, CEO and President of the company.
Kent Swanson purchased 27,977 shares on June 11 and currently controls
450,000 shares of the company. Kent Swanson serves as a Director and
Compensation Committee Chairman.
Jon Wickwire purchased 20,000 shares on May 8 and currently controls 363
,139 shares of the company. Jon Wickwire serves as a Director and Chairman
of Corporate Governance and Nominating Committees.
Financials
The company reported second-quarter financial results on August 9, with the
following highlights:
Revenue $8.2 million
Net income $0.7 million
Cash $1.2 million
On August 28 Bacterin announced the closing of a $25 million non-dilutive
financing with an affiliate of OrbiMed Advisors LLC. The financing will
enable Bacterin to execute its growth strategy through anticipated
profitability.
Under the terms of the agreement, Bacterin initially received $20 million
and has the ability to draw down an additional $5 million based upon the
achievement of mutually agreed upon revenue objectives prior to December 31,
2013. The company received net proceeds of approximately $10 million after
repayment of existing indebtedness as well as other transaction related fees
and expenses. Net proceeds will be used by the company for general working
capital purposes. No equity securities or warrants were issued as part of
the transaction.
Outlook
Guy Cook, CEO of Bacterin commented on August 9:
We have already achieved 45% of the low end of our annual revenue
guidance in the first half of this year. With our backorder behind us,
inventory levels up and planned clean room expansion for 3Q, we expect
continuing increased revenues in the second half of 2012 enabling us to
achieve our stated 2012 annual revenue guidance. Gross margin of 72% was
within our previous guidance and operating expenses decreased from the 1Q of
2012 enabling us to report positive EBITDA for the quarter, and a 54%
reduction in EBITDA loss for the first half of 2012 compared to the prior
periods.
We expect uptake in the wound care market for hMatrix to accelerate next
year with the expected issuance of a Q code by January 1, 2013. In the
interim, we are gaining traction with our shifted manufacturing and
marketing focus, beginning in the second quarter, for hMatrix to address
additional markets in sports medicine and reconstructive surgery.
OsteoSelect DBM putty is gaining sales momentum, leveraging recent
animal data equivalency to autologous bone graft, the current gold standard
for spinal fusion.
Data for our coatings remains on track for the second half of this year,
as well as independent data on OsteoSponge SC.
Bacterin gave a presentation on September 6, at Stifel Nicolaus 2012
Healthcare Conference with more details on the upcoming milestones.
My analysis
There have been 16 insider buy transactions and has been only one insider
sell transaction this year. There are upcoming catalysts pending for this
year and 2013. I believe the current share price is a good entry point for
the stock based on the insider trading activity and the upcoming milestones.
2. Codexis (CDXS) is a developer of cost-advantaged processes for the
production of biofuels, bio-based chemicals and pharmaceuticals. Codexis'
product lines include CodeXyme cellulase enzymes and CodeXol detergent
alcohol. Partners and customers include global leaders such as Merck (MRK),
Pfizer (PFE) and Teva (TEVA).
(click to enlarge)
Insider buys
David O'Toole purchased 5,000 shares on September 13-14, and currently holds
55,000 shares of the company. David O'Toole serves as Chief Financial
Officer and Senior Vice President of the company.
Financials
The company reported second-quarter financial results on August 9, with the
following highlights:
Revenue $22.9 million
Net loss $5.5 million
Cash $57.4 million
Shares outstanding 36.3 million
Cash per share $1.58
Outlook
Codexis adjusted its revenue forecast for the full year 2012 and now expects
a decline in total revenues relative to its full year 2011 total revenues
of $124 million. The company also now expects 2012 Adjusted EBITDA to be
negative and anticipates its year-end cash, cash equivalents, and marketable
securities, excluding any special items, to be approximately $50 million.
John Nicols, President and CEO of Codexis commented on August 9:
In pharmaceutical products, we are revising our forecast to account for
a shift in timing of orders for certain on-patent products. As a result, we
now forecast total product sales in line with last year's result of $49
million.
My analysis
There have been one insider buy transaction and two insider sell
transactions this year. I am not expecting the company to be profitable this
year. The company has a cash position of $1.58 per share which I would
expect to act like a support for the stock. I have a neutral bias for the
stock currently.
3. MRI Interventions (MRIC.OB) is a publicly traded company creating
innovative platforms for performing the next generation of minimally
invasive surgical procedures in the brain and heart. Utilizing a hospital's
existing MRI suite, the company's FDA-cleared ClearPoint system is designed
to enable a range of minimally invasive procedures in the brain. MRI
Interventions has a co-development and co-distribution agreement with
Brainlab, a leader in software-driven medical technology, relating to the
ClearPoint system. In partnership with Siemens Healthcare (SI), MRI
Interventions is developing the ClearTrace system to enable MRI-guided
catheter ablations to treat cardiac arrhythmias, including atrial
fibrillation. Building on the imaging power of MRI, the company's
interventional platforms strive to improve patient care while reducing
procedure costs and times. MRI Interventions is also working with Boston
Scientific Corporation (BSX) to incorporate its MRI-safety technologies into
Boston Scientific's implantable leads for cardiac and neurological
applications.
(click to enlarge)
Insider buys
Bruce Conway purchased 4,000 shares on September 14 and 18,750 shares on
September 12-13. Bruce Conway has purchased 156,698 shares this year. Bruce
Conway serves as a director of the company.
Financials
The company reported second-quarter financial results on August 14, with the
following highlights:
Revenue $1.1 million
Net loss $0.6 million
Cash $1.2 million
The company announced on July 5 that it has completed a private placement
equity financing. In the financing, MRI Interventions received gross
proceeds of $6 million from the sale of approximately 5.45 million units at
a purchase price of $1.10 per unit.
Outlook
Management believes that the company's existing cash resources, including
funds received in July 2012, together with cash generated from sales of
products, will be sufficient to meet anticipated cash requirements through
the first quarter of 2013.
My analysis
There have been 16 insider buy transactions since the May 2012 initial
public offering. There has not been any insider selling since the IPO. I
believe the stock could be a good pick here based on the insider trading
activity and a very promising product.
4. AtriCure (ATRC) is a medical device company and a leader in developing,
manufacturing and selling innovative cardiac surgical ablation systems
designed to create precise lesions, or scars, in cardiac, or heart, tissue
for the treatment of atrial fibrillation, or AF, and systems for the
exclusion of the left atrial appendage. The company believes cardiothoracic
surgeons are adopting its ablation products for the treatment of AF during
concomitant open-heart surgical procedures and sole-therapy minimally
invasive procedures. AF affects more than 5.5 million people worldwide and
predisposes them to a five-fold increased risk of stroke. The FDA has not
cleared or approved certain AtriCure products for the treatment of AF or a
reduction in the risk of stroke.
(click to enlarge)
Insider buys
Mark Lanning purchased 11,006 shares on September 14 and currently holds
25,000 shares of the company. Mark Lanning serves as a director of the
company.
Michael Hooven purchased 6,880 shares during September 7-14 and
currently controls 758,513 shares of the company. Michael Hooven serves as a
director of the company.
Financials
The company reported second-quarter financial results on August 2, with the
following highlights:
Revenue $18.3 million
Net loss $1.3 million
Cash $15.0 million
Outlook
Given the recently announced management transition, the company is
suspending its financial guidance until it hires a new Chief Executive
Officer and that person is comfortable resuming guidance.
My analysis
The stock has a $3.5 price target from the Point and Figure chart. There
have been nine insider buy transactions and 12 insider sell transactions
this year. I have a neutral bias for the stock currently based on the
insider trading activity and the lack of guidance from the company.
5. Sarepta Therapeutics (SRPT) -- formerly AVI BioPharma -- is focused on
developing first-in-class RNA-based therapeutics to improve and save the
lives of people affected by serious and life-threatening rare and infectious
diseases. The company's diverse pipeline includes its lead program
eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments
for some of the world's most lethal infectious diseases. Sarepta aims to
build a leading, independent biotech company dedicated to translating its
RNA-based science into transformational therapeutics for patients who face
significant unmet medical needs.
(click to enlarge)
Insider buys
Kathleen Behrens purchased 17,500 shares on September 7, and currently holds
36,666 shares of the company. Kathleen Behrens serves as a director of the
company.
Financials
The company reported second-quarter financial results on August 7, with the
following highlights:
Revenue $11.2 million
Operating loss $5.6 million
Cash $24.5 million
Outlook
On August 2, 2012, Sarepta received a stop-work order on the Ebola virus
portion of the U.S. government contract for Advanced Development of
Hemorrhagic Fever Virus Therapeutics due to recently imposed funding
constraints. The stop-work order does not apply to the Marburg portion of
the contract. If the stop-work order is not lifted, Sarepta anticipates 2012
full year revenue will be in the $37 to $43 million range and operating
loss will be in the $25 to $30 million range.
(click to enlarge)
Upcoming milestones
(click to enlarge)
Sarepta announced on July 24 that treatment with its exon-skipping compound,
eteplirsen, achieved a significant clinical benefit on the primary clinical
outcome, the 6-minute walk test (6MWT), over a placebo/delayed treatment
cohort in a Phase IIb trial in Duchenne muscular dystrophy [DMD] patients.
Eteplirsen administered once weekly at 50mg/kg over 36 weeks resulted in a
69.4 meter benefit compared with patients who received placebo for 24 weeks
followed by 12 weeks of treatment with eteplirsen in the open-label
extension. In the predefined prospective analysis of the study's intent-to-
treat [ITT] population on the primary clinical outcome measure, the change
in 6MWT distance from baseline, eteplirsen-treated patients who received
50mg/kg of the drug weekly (n=4) demonstrated a decline of 8.7 meters in
distance walked from baseline (mean=396.0 meters), while patients who
received placebo/delayed-eteplirsen treatment for 36 weeks (n=4) showed a
decline of 78.0 meters from baseline (mean=394.5 meters), for a
statistically significant treatment benefit of 69.4 meters over 36 weeks (p
≤0.019). The 48-week data from this study will be presented on October 9-13.
(click to enlarge)
Duchenne Muscular Dystrophy [DMD] is one of the most common fatal genetic
disorders to affect children around the world. Approximately one in every 3,
500 boys worldwide is affected with DMD. Girls are rarely affected by the
disorder. DMD is a devastating and incurable muscle-wasting disease
associated with specific inborn errors in the gene that codes for dystrophin
, a protein that plays a key structural role in muscle fiber function.
Symptoms usually appear in children by age three. Progressive muscle
weakness of the legs and pelvis eventually spreads to the arms, neck and
other areas. By age 10, braces may be required for walking, and most
patients require full-time use of a wheelchair by age 12. Eventually, this
progresses to complete paralysis and increasing difficulty in breathing due
to respiratory muscle dysfunction requiring ventilatory support, and cardiac
muscle dysfunction leading to heart failure. The condition is terminal, and
death usually occurs before the age of 30. The outpatient cost of care for
a non-ambulatory DMD patient is very high. There is currently no cure for
DMD, but for the first time ever there are promising therapies in, or moving
into, development.
(click to enlarge)
Sarepta announced September 4, that the U.S. Department of Defense [DoD] is
extending the period of the temporary stop-work order on the Ebola portion
of the company's pre-existing contract with JPM-TMT for advanced development
of therapeutics for both Marburg virus and Ebola virus. By September 30,
2012, the DoD will either: (1) terminate the Ebola portion of the contract;
(2) cancel the stop-work order; or (3) again extend the stop-work order
period.
News
Sarepta announced September 18, that the U.S. Food and Drug Administration [
FDA] has granted Fast Track status for the development of its lead
infectious disease drug candidates, AVI-7288 and AVI-7537, for the treatment
of Marburg virus and Ebola virus, respectively. Currently, the JPM-TMT's
Ebola programs, including development of AVI-7537, remain under a temporary
stop-work order due to funding constraints.
My analysis
The stock has a $23.5 price target from the Point and Figure chart. There
have been two insider buy transactions and there has been one insider sell
transaction this year. The stock has two near-term catalysts. By September
30, the DoD will decide the faith of the Ebola program. And the 48-week data
from the DMD study will be presented on October 9-13. If both of these
catalysts turn out to be positive the stock could be trading at $20. If both
of these catalysts turn out to be negative the stock could be trading at $
10. | T**********s
发帖数: 647 | | f******t
发帖数: 478 | 3 这内部自己买进，对于我等散户是好消息还是坏消息？是该跟进还是趁早抛出？ | q********g
发帖数: 10694 | 4 通常是内部买进说明内部人了解公司的经营，对公司的未来有信心。个人感觉是跟进。
【在 f******t 的大作中提到】
: 这内部自己买进，对于我等散户是好消息还是坏消息？是该跟进还是趁早抛出？
| q********g
发帖数: 10694 | |
|
